ePT--the Electronic Newsletter of Pharmaceutical Technology
West Point, PA (Jul. 31)?A survey of 150 US pharmacists found that nearly 80% believe that "multiple look-alike medications" make it difficult for consumers to identify the correct medication, especially when the drugs are moved to unlabeled containers.
West Point, PA (Jul. 31) – A survey of 150 US pharmacists found that nearly 80% believe that "multiple look-alike medications" make it difficult for consumers to identify the correct medication, especially when the drugs are moved to unlabeled containers. The study was conducted by Paragon Research & Consulting and sponsored by Colorcon, Inc. (www.colorcon.com), producer of coatings and excipients. A press release summarizing the survey (http://www.primezone.com/newsroom/news.html?d=102806) notes that pharmacy boards in California, Wyoming, and Oregon now require that prescription-medication labels include the color, shape, and identifying marks appearing on the tablets or capsules.
"Clear identification of medications by both pharmacists and patients is extremely important in reducing medication error," the statement quotes James Carder, Executive Director of the Wyoming Board of Pharmacy. "As the number of discrete solid dose tablet offerings continues to grow, differentiation is becoming more difficult for pharmacists, nurses, physicians, patients and caregivers, and errors are hard to avoid when so many of these medications look alike. Clearly identifiable medicines can help reduce dispensing error, and help ensure patient safety and compliance."
The pharmacists surveyed rated color and shape as the traits consumers use most often to identify medications, followed by imprinted numerical codes, drug names, or logos. Look-alike medications (79% of respondents) and unreadable imprinted codes (74%) topped the pharmacists' list of factors contributing to identification difficulties.
Nearly 70% of respondents reported patients ask them for help identifying out-of-the-package tablets or capsules least once a week. (Nearly 40% of the reported identification requests come from customers aged 65-84, and 36% from customers aged 45-64.)
A 2004 survey conducted by an expert committee of the US Pharmacopeia, the Colorcon report notes, indicated that practitioners and pharmacists believe that current tablet identification tools should be improved and that the industry and FDA should work together toward this goal (Expert Committee Meeting Summaries: Safe Medication Use Expert Committee, U.S. Pharmacopeia. Oct. 11–12, 2004. http://www.usp.org/USPNF/meetingSummaries/2004/10-11.html).
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.